Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

145.23 -2.25 (-1.53%)
Streaming Delayed Price Updated: 9:50 AM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
56 57 Next >
News headline image
Elsevier Launches New Pharmapendium, Empowering Pharma Companies to Bring Novel Drugs to Market Faster and Increase Success of Regulatory Submissions
London, United Kingdom--(Newsfile Corp. - October 10, 2023) - Elsevier, a global leader in information and data analytics, has launched... 
Via Newsfile
Topics Animal Testing
News headline image
3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’ ↗
These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
News headline image
Protecting Cannabis Products & More: New Sustainable Child-Resistant Packaging By Dymapak ↗
Dymapak, a global manufacturer specializing in innovative child-resistant packaging solutions for various industries, has introduced a child-resistant Consumer Packaged Goods (CPG) packaging... 
Via Benzinga
Topics Cannabis
News headline image
Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2... 
Via Benzinga
News headline image
Novartis Shares Decline As Spin Off Sandoz's Market Debut Falls Short of Expected Valuation ↗
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) enters a new era as a standalone player in generic and biosimilar medicines. 
Via Benzinga
News headline image
SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today ↗
Sandoz (SDZNY) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff from Novartis. 
Via InvestorPlace
News headline image
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares ↗
3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock. 
Via Benzinga
News headline image
Cal-Maine Foods, A10 Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift ↗
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy... 
Via Benzinga
News headline image
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration ↗
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
News headline image
Novartis' Investigational Therapy Shows Promising Action In Rare Kidney Disease ↗
Novartis AG (NYSE: NVS) announced topline results from the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study at nine months of iptacopan, an investigational factor B inhibitor targeting... 
Via Benzinga
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
News headline image
Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer ↗
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies... 
Via Benzinga
News headline image
Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside ↗
JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid immunoglobulin-like lectin) receptors on immune cells that are drivers... 
Via Benzinga
News headline image
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
News headline image
Health Insurer Centene Streamlines - Plans Massive Layoffs To Cut Costs: Report ↗
Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and accelerate profits over the years. 
Via Benzinga
Topics Workforce
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗
 
Via Benzinga
News headline image
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs ↗
Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it  
Via Benzinga
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer ↗
Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic  
Via Benzinga
News headline image
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement ↗
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
News headline image
AI To Revolutionize Clinical Trials And Diagnostics ↗
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
News headline image
From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Preventable Vaccines Market May See a Big Move : AstraZeneca, GlaxoSmithKline, Merck
Stay up-to-date with Preventable Vaccines Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
News headline image
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories ↗
Bloomberg 
Via Benzinga
News headline image
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact ↗
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS). 
Via Benzinga
News headline image
AMC Stock Alert: Adam Aron Teases New Chocolate, Wine Brands for AMC ↗
AMC Entertainment (AMC) stock is a hot topic on Friday after the movie theater chain's CEO teased that new products are on the way. 
Via InvestorPlace
News headline image
Why Is Canopy Growth (CGC) Stock Up 14% Today? ↗
Canopy Growth (CGC) stock is rising higher on Friday after the cannabis company announced it won't fund BioSteel Sports Nutrition any longer. 
Via InvestorPlace
Topics Cannabis
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.